RecruitingNot ApplicableNCT04581122

A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components

Zhongshan Hospital

Sponsor

Shanghai Zhongshan Hospital

Enrollment

1,500 participants

Start Date

Sep 1, 2020

Study Type

INTERVENTIONAL

Conditions

Progression

Summary

A multiple-center study on the effect of different ways of lymph node dissection on the prognosis of less than 3cm ground glass nodules with more than solid components

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

Aged between 18 and 75 years;
GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT);
The maximum diameter of the GGO is smaller than 3cm;
The maximum diameter of the solid component in the GGO is more than 50%;
The patient is able to undergo the lobectomy
The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion Criteria6

\-
Patients meeting any of the following criteria are not eligible for this trial:
Patients with a history of using immunosuppressive or hormonal drugs;
Patients receiving radiotherapy or chemotherapy;
Patients who fail to comply with our follow-up strategy;
Other situations that are not in conformity with the standards and requirements of this trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELymphadenectomy

Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group

Locations(1)

Jiang Wei

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04581122

Related Trials

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

NCT049746711 location